COVID-19 Fuels Massive & Sustainable Growth in Molecular Diagnostics
...
Already a member? Log in here
Labs, Universities and Even Computer Companies Target Point-of-Care COVID-19 Test Development
...
Already a member? Log in here
Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration
...
Already a member? Log in here
Diagnostic Deals: Lab Corp & Quest to Continue Targeting Small and Independent Labs for Acquisition
PAMA price cuts were supposed to drive consolidation in the lab market. The expectation was that price pressures would make it impossible for smaller labs to remain independent, rendering them juicy targets for the likes of
Already a member? Log in here
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will apparently continue as stand-alones in the coming year, one because it wants to and the other because it has to.
Already a member? Log in here